Tumor lymphocytes in patients with advanced ovarian cancer: Changes during in vitro culture and implications for immunotherapy

Gynecologic Oncology

Volumn 65, Issue 3, 1997, Pages 391-398

  Han, X ^a   Papadopoulos, A J ^a   Ruparelia, V ^a   Devaja, O ^a   Raju, K S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASCITES FLUID CYTOLOGY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; HUMAN; OVARY CANCER; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 0031172649     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4668     Document Type: Article

References (23)

1. 1. Allavena P, Zanaboni F, Rosini S, et al.: LAK activity or TAL and PBL isolated from patients with ascites ovarian tumours. J Natl Cancer Inst 77:863-868, 1986
2. 2. Berek JS, Bast RC, Hacker NF, et al: Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet Gynecol 64:708-714, 1984
3. 3. Boyer P, Berek JS, Zighelboim J: Lymphocyte activation by recombinant interleukin-2 in ovarian cancer patients. Obstet Gynecol 73:793-797, 1989
4. 4. Ferrini S, Biassoni R, Moretta A, et al: Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascites fluid: phenotypic and functional characterisation of T cell clones capable of lysing autologous carcinoma cells. Int J Cancer 36:337-343, 1985
5. 5. Ionnides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, Freedman RS: Tumour cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 51:4257-4265, 1991
6. 6. Lacki J, Markowska J, Wiktorewicz K: Phenotype of lymphocyte in ovarian peritoneal fluid. Eur J Gynaecol Oncol 13:475-479, 1992
7. 7. Lichtenstein A, Spina C, Berek JS, Zighelboim J: Intraperitoneal administration of human rIFNα in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity. Cancer Res 48:5853-5859, 1988
8. 8. Melioli G, Baldini E, Mingari MC, et al.: Phenotypic and functional characteristics of TALs in patients with malignant ascites receiving intraperitoneal infusions or rIL-2. Int J Cancer 43:231-234, 1989
9. 9. Melioli G, Ferrari I, Casartelli G, Ragni N: Lymphocytes isolated from the peritoneal fluid of women with advanced ovarian carcinoma differ significantly from autologous peripheral blood lymphocytes. Gynecol Oncol 48:301-307, 1993
10. 10. Rambaldi A, Introna M, Colotta F, et al: Intraperitoneal administration of IFNβ in ovarian cancer patients. Cancer 56:294-301, 1985
11. 11. Berek JS, Hacker NF (Eds.). Practical Gynecologic Oncology, Baltimore, Williams and Wilkins, 1989, pp 331-335
12. 12. Fisher B, Packard BS, Read EJ, et al.: Tumour localisation of adoptively transferred indium-111 labelled tumour infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7:250-261, 1989
13. 13. Morgan DA, Ruscetti IW, Gallo R: Selective in vitro growth of tumour lymphocytes for normal human bone marrow. Science 193:1007, 1976
14. 14. Yamamoto JK, Farrar WL, Johnson HM: IL-2 regulation of mitogen induction of immune Interferon γ in spleen cells and thymocytes. Cell Immunol 66:333, 1982
15. 15. Howard M, Matis L, Malek TR, et al.: IL-2 induces antigen reactive T cell lines to secrete BCGF-I. J Exp Med 158:2024, 1983
16. 16. Grimm EA, Robb R, Rith J, Neckers LM, Lachman LB, Wilson DJ, et al.: Lymphokine activated killer (LAK) cell phenomenon III. Evidence that 11-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine activated killer cells. J Exp Med 158:1356, 1983
17. 17. Berek JS: Intraperitoneal adoptive immunotherapy for peritoneal carcinoma. J Clin Oncol 8:1610-1612, 1990
18. 18. Beller U, Chachoua A, Speyer JL, et al: Phase IB study of low-dose intraperitoneal recombinant IL-2 in patients with refractory advanced ovarian cancer: rationale and preliminary report. Gynecol Oncol 34:407-412, 1989
19. 19. Melioli G, Sertoli MR, Bruzzone N, et al.: Phase I study of recombinant IL-2 intraperitoneal infusion in patients with neoplastic ascites: toxic effects and immunologie results. Am J Clin Oncol 14:231-237, 1991
20. 20. Shepherd JH: Revised FIGO staging for gynaecological cancer. Br J Obstet Gynecol 96:889-892, 1989
21. 21. Papadopoulos AJ, Han X, Matossian-Rogers A, Raju KS: Induction of immunocellular resistance to IL-2 activated lymphocytes within ovarian carcinoma cells. Gynecol Oncol 57:388-394, 1995
22. 22. Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA: Lymphokine activated killer cells (LAK) cells: analysis of factors relevant to the immunotherapy of human cancer. Cancer 55:1327-1333, 1985
23. 23. Han X, Itoh K, Balch C, Pellis NK: Recombinant interleukin-4 (I1-4) inhibits I1-2 induced activation of peripheral blood mononuclear cells. Lymphokine Res 7(3):227, 1988